Related Experiment Video
Updated: Dec 19, 2025
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
PD-1 Blockade in Chinese versus Western Patients with Melanoma
Alexander N Shoushtari1,2, Riyue Bao3,4, Jason J Luke5,4
1Memorial Sloan Kettering Cancer Center, New York, New York. shoushta@mskcc.org lukejj@upmc.edu.
Abstract:
In this trial of programmed cell death-1 (PD-1) blockade with toripalimab in previously treated Chinese patients with melanoma, unique histologic and molecular features may explain why the objective response rate is lower than those defined in Western populations. This work suggests future avenues for investigating mechanisms of melanoma formation and resistance to PD-1 blockade.See related article by Tang et al., p. 4250.
Insights
This study investigated programmed cell death-1 (PD-1) blockade in Chinese melanoma patients. Unique features in this population may explain lower response rates compared to Western patients, suggesting new research directions.
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Melanoma is a significant skin cancer.
- Programmed cell death-1 (PD-1) blockade is an immunotherapy for melanoma.
- Previous trials have shown varying response rates in different populations.
Purpose of the Study:
- To evaluate the efficacy of toripalimab, a PD-1 inhibitor, in previously treated Chinese melanoma patients.
- To explore potential histologic and molecular factors influencing treatment response in this cohort.
Main Methods:
- Clinical trial design involving toripalimab administration.
- Analysis of objective response rates.
- Investigation of unique histologic and molecular features in Chinese patients.
Main Results:
- The objective response rate in Chinese patients was lower than observed in Western populations.
- Distinct histologic and molecular characteristics were identified in the Chinese cohort.
- These features may contribute to differential treatment outcomes.
Conclusions:
- Unique patient characteristics in China may influence melanoma response to PD-1 blockade.
- Further research is needed to understand melanoma mechanisms and resistance to PD-1 inhibitors in diverse populations.
